Ulcerative colitis as a polymicrobial infection characterized by sustained broken mucus barrier

World Journal of Gastroenterology

Volumn 20, Issue 28, 2014, Pages 9468-9475

  Chen, Shui Jiao ^a   Liu, Xiao Wei ^a   Liu, Jian Ping ^a   Yang, Xi Yan ^a   Lu, Fang Gen ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Bacteria; Etiology; Infection; Mucus; Ulcerative colitis

Indexed keywords

PROBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; BACTERIAL IMMUNITY; BACTERIAL PHENOMENA AND FUNCTIONS; COLON FLORA; DISEASE ASSOCIATION; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TRACT FUNCTION; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; INTESTINE FLORA; MUCUS GLAND; MUCUS SECRETION; NONHUMAN; PERMEABILITY BARRIER; REVIEW; ULCERATIVE COLITIS; ANIMAL; COLITIS, ULCERATIVE; COLON; DRUG EFFECTS; INTESTINE MUCOSA; MICROBIOLOGY; MICROFLORA; MUCUS; PATHOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; COLITIS, ULCERATIVE; COLON; HUMANS; INTESTINAL MUCOSA; MICROBIOTA; MUCUS; PROBIOTICS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84908471774     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i28.9468     Document Type: Review

References (99)

1. Ooi CJ, Fock KM, Makharia GK, Goh KL, Ling KL, Hilmi I, Lim WC, Kelvin T, Gibson PR, Gearry RB, Ouyang Q, Sollano J, Manatsathit S, Rerknimitr R, Wei SC, Leung WK, de Silva HJ, Leong RW. The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol 2010; 25: 453-468 [PMID: 20370724 DOI: 10.1111/j.1440-1746.2010.06241.x]
2. Sood A, Midha V. Epidemiology of inflammatory bowel disease in Asia. Indian J Gastroenterol 2007; 26: 285-289 [PMID: 18431013]
3. Kannan N, Guruvayoorappan C. Protective effect of Bauhinia tomentosa on acetic acid induced ulcerative colitis by regulating antioxidant and inflammatory mediators. Int Immunopharmacol 2013; 16: 57-66 [PMID: 23538025 DOI: 10.1016/j.intimp.2013.03.008]
4. Criscuoli V, Modesto I, Orlando A, Cottone M. Mesalazine for the treatment of inflammatory bowel disease. Expert Opin Pharmacother 2013; 14: 1669-1678 [PMID: 23767798 DOI: 10.1517/14656566.2013.808622]
5. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 577-585 [PMID: 16480396]
6. Kellermayer R. Genetic drift. "Omics"as the filtering gateway between environment and phenotype: The inflammatory bowel diseases example. Am J Med Genet A 2010; 152A: 3022-3025 [PMID: 21108388 DOI: 10.1002/ajmg.a.33726]
7. Packey CD, Sartor RB. Interplay of commensal and pathogenic bacteria, genetic mutations, and immunoregulatory defects in the pathogenesis of inflammatory bowel diseases. J Intern Med 2008; 263: 597-606 [PMID: 18479259 DOI: 10.1111/j.1365-2796.2008.01962.x]
8. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641-1657 [PMID: 17499606]
9. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev 2002; 15: 79-94 [PMID: 11781268]
10. Johansson ME, Larsson JM, Hansson GC. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci USA 2011; 108 Suppl 1: 4659-4665 [PMID: 20615996 DOI: 10.1073/pnas.1006451107]
11. Fu J, Wei B, Wen T, Johansson ME, Liu X, Bradford E, Thomsson KA, McGee S, Mansour L, Tong M, McDaniel JM, Sferra TJ, Turner JR, Chen H, Hansson GC, Braun J, Xia L. Loss of intestinal core 1-derived O-glycans causes spontaneous colitis in mice. J Clin Invest 2011; 121: 1657-1666 [PMID: 21383503 DOI: 10.1172/JCI45538]
12. Hansson GC. Role of mucus layers in gut infection and inflammation. Curr Opin Microbiol 2012; 15: 57-62 [PMID: 22177113 DOI: 10.1016/j.mib.2011.11.002]
13. Kim DY, Takeuchi K, Ishinaga H, Kishioka C, Suzuki S, Basbaum C, Majima Y. Roxithromycin suppresses mucin gene expression in epithelial cells. Pharmacology 2004; 72: 6-11 [PMID: 15292649]
14. Dharmani P, Srivastava V, Kissoon-Singh V, Chadee K. Role of intestinal mucins in innate host defense mechanisms against pathogens. J Innate Immun 2009; 1: 123-135 [PMID: 20375571 DOI: 10.1159/000163037]
15. Lindén SK, Florin TH, McGuckin MA. Mucin dynamics in intestinal bacterial infection. PLoS One 2008; 3: e3952 [PMID: 19088856 DOI: 10.1371/journal.pone.0003952]
16. Bergstrom KS, Kissoon-Singh V, Gibson DL, Ma C, Montero M, Sham HP, Ryz N, Huang T, Velcich A, Finlay BB, Chadee K, Vallance BA. Muc2 protects against lethal infectious colitis by disassociating pathogenic and commensal bacteria from the colonic mucosa. PLoS Pathog 2010; 6: e1000902 [PMID: 20485566 DOI: 10.1371/journal.ppat.1000902]
17. Swidsinski A, Loening-Baucke V, Herber A. Mucosal flora in Crohn's disease and ulcerative colitis - an overview. J Physiol Pharmacol 2009; 60 Suppl 6: 61-71 [PMID: 20224153]
18. Qin X. Etiology of inflammatory bowel disease: a unified hypothesis. World J Gastroenterol 2012; 18: 1708-1722 [PMID: 22553395 DOI: 10.3748/wjg.v18.i15.1708]
19. Dharmani P, Leung P, Chadee K. Tumor necrosis factor-α and Muc2 mucin play major roles in disease onset and progression in dextran sodium sulphate-induced colitis. PLoS One 2011; 6: e25058 [PMID: 21949848 DOI: 10.1371/journal. pone.0025058]
20. Kawashima H. Roles of the gel-forming MUC2 mucin and its O-glycosylation in the protection against colitis and colorectal cancer. Biol Pharm Bull 2012; 35: 1637-1641 [PMID: 23037153]
21. Stremmel W. [Mucosal protection by phosphatidylcholine as new therapeutic concept in ulcerative colitis]. Z Gastroenterol 2013; 51: 384-389 [PMID: 23585269 DOI: 10.1055/s-0033-1335042]
22. Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep 2010; 12: 319-330 [PMID: 20703838 DOI: 10.1007/s11894-010-0131-2]
23. Shirazi T, Longman RJ, Corfield AP, Probert CS. Mucins and inflammatory bowel disease. Postgrad Med J 2000; 76: 473-478 [PMID: 10908374]
24. Dorofeyev AE, Vasilenko IV, Rassokhina OA, Kondratiuk RB. Mucosal barrier in ulcerative colitis and Crohn's disease. Gastroenterol Res Pract 2013; 2013: 431231 [PMID: 23737764 DOI: 10.1155/2013/431231]
25. Gersemann M, Wehkamp J, Stange EF. Innate immune dysfunction in inflammatory bowel disease. J Intern Med 2012; 271: 421-428 [PMID: 22324936 DOI: 10.1111/j.1365-2796.2012.02515.x]
26. Zheng X, Tsuchiya K, Okamoto R, Iwasaki M, Kano Y, Sakamoto N, Nakamura T, Watanabe M. Suppression of hath1 gene expression directly regulated by hes1 via notch signaling is associated with goblet cell depletion in ulcerative colitis. Inflamm Bowel Dis 2011; 17: 2251-2260 [PMID: 21987298 DOI: 10.1002/ibd.21611]
27. Gersemann M, Stange EF, Wehkamp J. From intestinal stem cells to inflammatory bowel diseases. World J Gastroenterol 2011; 17: 3198-3203 [PMID: 21912468 DOI: 10.3748/wjg.v17. i27.3198]
28. Johansson ME. Fast renewal of the distal colonic mucus layers by the surface goblet cells as measured by in vivo labeling of mucin glycoproteins. PLoS One 2012; 7: e41009 [PMID: 22815896 DOI: 10.1371/journal.pone.0041009]
29. Håkansson A, Tormo-Badia N, Baridi A, Xu J, Molin G, Hagslätt ML, Karlsson C, Jeppsson B, Cilio CM, Ahrné S. Immunological alteration and changes of gut microbiota after dextran sulfate sodium (DSS) administration in mice. Clin Exp Med 2014; Epub ahead of print [PMID: 24414342]
30. Stremmel W, Gauss A. Lecithin as a therapeutic agent in ulcerative colitis. Dig Dis 2013; 31: 388-390 [PMID: 24246994 DOI: 10.1159/000354707]
31. Ohkusa T, Yoshida T, Sato N, Watanabe S, Tajiri H, Okayasu I. Commensal bacteria can enter colonic epithelial cells and induce proinflammatory cytokine secretion: a possible pathogenic mechanism of ulcerative colitis. J Med Microbiol 2009; 58: 535-545 [PMID: 19369513 DOI: 10.1099/jmm.0.005801-0]
32. Hotte NS, Salim SY, Tso RH, Albert EJ, Bach P, Walker J, Dieleman LA, Fedorak RN, Madsen KL. Patients with inflammatory bowel disease exhibit dysregulated responses to microbial DNA. PLoS One 2012; 7: e37932 [PMID: 22649567 DOI: 10.1371/journal.pone.0037932]
33. Lee J, Mo JH, Katakura K, Alkalay I, Rucker AN, Liu YT, Lee HK, Shen C, Cojocaru G, Shenouda S, Kagnoff M, Eckmann L, Ben-Neriah Y, Raz E. Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol 2006; 8: 1327-1336 [PMID: 17128265]
34. Jijon H, Backer J, Diaz H, Yeung H, Thiel D, McKaigney C, De Simone C, Madsen K. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 2004; 126: 1358-1373 [PMID: 15131797]
35. Rana SV, Sharma S, Malik A, Kaur J, Prasad KK, Sinha SK, Singh K. Small intestinal bacterial overgrowth and orocecal transit time in patients of inflammatory bowel disease. Dig Dis Sci 2013; 58: 2594-2598 [PMID: 23649377 DOI: 10.1007/s10620-013-2694-x]
36. Ohkusa T, Sato N, Ogihara T, Morita K, Ogawa M, Okayasu I. Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol 2002; 17: 849-853 [PMID: 12164960]
37. Koido S, Ohkusa T, Kajiura T, Shinozaki J, Suzuki M, Saito K, Takakura K, Tsukinaga S, Odahara S, Yukawa T, Mitobe J, Kajihara M, Uchiyama K, Arakawa H, Tajiri H. Long-term alteration of intestinal microbiota in patients with ulcerative colitis by antibiotic combination therapy. PLoS One 2014; 9: e86702 [PMID: 24489770 DOI: 10.1371/journal.pone.0086702]
38. Mukhopadhya I, Thomson JM, Hansen R, Berry SH, El-Omar EM, Hold GL. Detection of Campylobacter concisus and other Campylobacter species in colonic biopsies from adults with ulcerative colitis. PLoS One 2011; 6: e21490 [PMID: 21738679 DOI: 10.1371/journal.pone.0021490]
39. Kalischuk LD, Inglis GD, Buret AG. Campylobacter jejuni induces transcellular translocation of commensal bacteria via lipid rafts. Gut Pathog 2009; 1: 2 [PMID: 19338680 DOI: 10.1186/1757-4749-1-2]
40. Lamb-Rosteski JM, Kalischuk LD, Inglis GD, Buret AG. Epidermal growth factor inhibits Campylobacter jejuni-induced claudin-4 disruption, loss of epithelial barrier function, and Escherichia coli translocation. Infect Immun 2008; 76: 3390-3398 [PMID: 18490463 DOI: 10.1128/IAI.01698-07]
41. Sepehri S, Khafipour E, Bernstein CN, Coombes BK, Pilar AV, Karmali M, Ziebell K, Krause DO. Characterization of Escherichia coli isolated from gut biopsies of newly diagnosed patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 1451-1463 [PMID: 21674703 DOI: 10.1002/ibd.21509]
42. Bohr UR, Glasbrenner B, Primus A, Zagoura A, Wex T, Malfertheiner P. Identification of enterohepatic Helicobacter species in patients suffering from inflammatory bowel disease. J Clin Microbiol 2004; 42: 2766-2768 [PMID: 15184464]
43. Thomson JM, Hansen R, Berry SH, Hope ME, Murray GI, Mukhopadhya I, McLean MH, Shen Z, Fox JG, El-Omar E, Hold GL. Enterohepatic helicobacter in ulcerative colitis: potential pathogenic entities? PLoS One 2011; 6: e17184 [PMID: 21383845 DOI: 10.1371/journal.pone.0017184]
44. Saitoh S, Noda S, Aiba Y, Takagi A, Sakamoto M, Benno Y, Koga Y. Bacteroides ovatus as the predominant commensal intestinal microbe causing a systemic antibody response in inflammatory bowel disease. Clin Diagn Lab Immunol 2002; 9: 54-59 [PMID: 11777829]
45. Bullock NR, Booth JC, Gibson GR. Comparative composition of bacteria in the human intestinal microflora during remission and active ulcerative colitis. Curr Issues Intest Microbiol 2004; 5: 59-64 [PMID: 15460067]
46. Noor SO, Ridgway K, Scovell L, Kemsley EK, Lund EK, Jamieson C, Johnson IT, Narbad A. Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota. BMC Gastroenterol 2010; 10: 134 [PMID: 21073731 DOI: 10.1186/1471-230X-10-134]
47. Mann ER, You J, Horneffer-van der Sluis V, Bernardo D, Omar Al-Hassi H, Landy J, Peake ST, Thomas LV, Tee CT, Lee GH, Hart AL, Yaqoob P, Knight SC. Dysregulated circulating dendritic cell function in ulcerative colitis is partially restored by probiotic strain Lactobacillus casei Shirota. Mediators Inflamm 2013; 2013: 573576 [PMID: 23970814 DOI: 10.1155/2013/573576]
48. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, Akira S, Takeda K, Lee J, Takabayashi K, Raz E. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004; 126: 520-528 [PMID: 14762789]
49. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004; 118: 229-241 [PMID: 15260992]
50. Liévin-Le Moal V, Servin AL. The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota. Clin Microbiol Rev 2006; 19: 315-337 [PMID: 16614252]
51. Johansson ME, Thomsson KA, Hansson GC. Proteomic analyses of the two mucus layers of the colon barrier reveal that their main component, the Muc2 mucin, is strongly bound to the Fcgbp protein. J Proteome Res 2009; 8: 3549-3557 [PMID: 19432394 DOI: 10.1021/pr9002504]
52. van der Post S, Subramani DB, Bäckström M, Johansson ME, Vester-Christensen MB, Mandel U, Bennett EP, Clausen H, Dahlén G, Sroka A, Potempa J, Hansson GC. Site-specific O-glycosylation on the MUC2 mucin protein inhibits cleavage by the Porphyromonas gingivalis secreted cysteine protease (RgpB). J Biol Chem 2013; 288: 14636-14646 [PMID: 23546879 DOI: 10.1074/jbc.M113.459479]
53. Collado MC, Derrien M, Isolauri E, de Vos WM, Salminen S. Intestinal integrity and Akkermansia muciniphila, a mucindegrading member of the intestinal microbiota present in infants, adults, and the elderly. Appl Environ Microbiol 2007; 73: 7767-7770 [PMID: 17933936]
54. Sonnenburg JL, Angenent LT, Gordon JI. Getting a grip on things: how do communities of bacterial symbionts become established in our intestine? Nat Immunol 2004; 5: 569-573 [PMID: 15164016]
55. Johansson ME, Phillipson M, Petersson J, Velcich A, Holm L, Hansson GC. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci USA 2008; 105: 15064-15069 [PMID: 18806221 DOI: 10.1073/pnas.0803124105]
56. Petersson J, Schreiber O, Hansson GC, Gendler SJ, Velcich A, Lundberg JO, Roos S, Holm L, Phillipson M. Importance and regulation of the colonic mucus barrier in a mouse model of colitis. Am J Physiol Gastrointest Liver Physiol 2011; 300: G327-G333 [PMID: 21109593 DOI: 10.1152/ajpgi.00422.2010]
57. Gaudier E, Rival M, Buisine MP, Robineau I, Hoebler C. Butyrate enemas upregulate Muc genes expression but decrease adherent mucus thickness in mice colon. Physiol Res 2009; 58: 111-119 [PMID: 18198997]
58. Burger-van Paassen N, Vincent A, Puiman PJ, van der Sluis M, Bouma J, Boehm G, van Goudoever JB, van Seuningen I, Renes IB. The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection. Biochem J 2009; 420: 211-219 [PMID: 19228118 DOI: 10.1042/BJ20082222]
59. Sánchez B, Urdaci MC, Margolles A. Extracellular proteins secreted by probiotic bacteria as mediators of effects that promote mucosa-bacteria interactions. Microbiology 2010; 156: 3232-3242 [PMID: 20864471 DOI: 10.1099/mic.0.044057-0]
60. Zen Y, Harada K, Sasaki M, Tsuneyama K, Katayanagi K, Yamamoto Y, Nakanuma Y. Lipopolysaccharide induces overexpression of MUC2 and MUC5AC in cultured biliary epithelial cells: possible key phenomenon of hepatolithiasis. Am J Pathol 2002; 161: 1475-1484 [PMID: 12368220]
61. García-Miguel M, González MJ, Quera R, Hermoso MA. Innate immunity modulation by the IL-33/ST2 system in intestinal mucosa. Biomed Res Int 2013; 2013: 142492 [PMID: 23484079 DOI: 10.1155/2013/142492]
62. Willing B, Halfvarson J, Dicksved J, Rosenquist M, Järnerot G, Engstrand L, Tysk C, Jansson JK. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm Bowel Dis 2009; 15: 653-660 [PMID: 19023901 DOI: 10.1002/ibd.20783]
63. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65 [PMID: 20203603 DOI: 10.1038/nature08821]
64. Lupp C, Robertson ML, Wickham ME, Sekirov I, Champion OL, Gaynor EC, Finlay BB. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2007; 2: 119-129 [PMID: 18005726]
65. Tong M, Li X, Wegener Parfrey L, Roth B, Ippoliti A, Wei B, Borneman J, McGovern DP, Frank DN, Li E, Horvath S, Knight R, Braun J. A modular organization of the human intestinal mucosal microbiota and its association with inflammatory bowel disease. PLoS One 2013; 8: e80702 [PMID: 24260458 DOI: 10.1371/journal.pone.0080702]
66. Wang W, Chen L, Zhou R, Wang X, Song L, Huang S, Wang G, Xia B. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J Clin Microbiol 2014; 52: 398-406 [PMID: 24478468 DOI: 10.1128/JCM.01500-13]
67. Kumari R, Ahuja V, Paul J. Fluctuations in butyrate-producing bacteria in ulcerative colitis patients of North India. World J Gastroenterol 2013; 19: 3404-3414 [PMID: 23801832 DOI: 10.3748/wjg.v19.i22.3404]
68. Nemoto H, Kataoka K, Ishikawa H, Ikata K, Arimochi H, Iwasaki T, Ohnishi Y, Kuwahara T, Yasutomo K. Reduced diversity and imbalance of fecal microbiota in patients with ulcerative colitis. Dig Dis Sci 2012; 57: 2955-2964 [PMID: 22623042 DOI: 10.1007/s10620-012-2236-y]
69. Vigsnæs LK, Brynskov J, Steenholdt C, Wilcks A, Licht TR. Gram-negative bacteria account for main differences between faecal microbiota from patients with ulcerative colitis and healthy controls. Benef Microbes 2012; 3: 287-297 [PMID: 22968374 DOI: 10.3920/BM2012.0018]
70. Kabeerdoss J, Sankaran V, Pugazhendhi S, Ramakrishna BS. Clostridium leptum group bacteria abundance and diversity in the fecal microbiota of patients with inflammatory bowel disease: a case-control study in India. BMC Gastroenterol 2013; 13: 20 [PMID: 23351032 DOI: 10.1186/1471-230X-13-20]
71. Pilarczyk-Zurek M, Chmielarczyk A, Gosiewski T, Tomusiak A, Adamski P, Zwolinska-Wcislo M, Mach T, Heczko PB, Strus M. Possible role of Escherichia coli in propagation and perpetuation of chronic inflammation in ulcerative colitis. BMC Gastroenterol 2013; 13: 61 [PMID: 23566070 DOI: 10.1186/1471-230X-13-61]
72. Lepage P, Häsler R, Spehlmann ME, Rehman A, Zvirbliene A, Begun A, Ott S, Kupcinskas L, Doré J, Raedler A, Schreiber S. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology 2011; 141: 227-236 [PMID: 21621540 DOI: 10.1053/j.gastro.2011.04.011]
73. Verma R, Verma AK, Ahuja V, Paul J. Real-time analysis of mucosal flora in patients with inflammatory bowel disease in India. J Clin Microbiol 2010; 48: 4279-4282 [PMID: 20861337 DOI: 10.1128/JCM.01360-10]
74. Khalil NA, Walton GE, Gibson GR, Tuohy KM, Andrews SC. In vitro batch cultures of gut microbiota from healthy and ulcerative colitis (UC) subjects suggest that sulphatereducing bacteria levels are raised in UC and by a proteinrich diet. Int J Food Sci Nutr 2014; 65: 79-88 [PMID: 23941288 DOI: 10.3109/09637486.2013.825700]
75. Dicksved J, Schreiber O, Willing B, Petersson J, Rang S, Phillipson M, Holm L, Roos S. Lactobacillus reuteri maintains a functional mucosal barrier during DSS treatment despite mucus layer dysfunction. PLoS One 2012; 7: e46399 [PMID: 23029509 DOI: 10.1371/journal.pone.0046399]
76. Zhou FX, Chen L, Liu XW, Ouyang CH, Wu XP, Wang XH, Wang CL, Lu FG. Lactobacillus crispatus M206119 exacer-bates murine DSS-colitis by interfering with inflammatory responses. World J Gastroenterol 2012; 18: 2344-2356 [PMID: 22654425 DOI: 10.3748/wjg.v18.i19.2344]
77. Sartor RB. Clinical applications of advances in the genetics of IBD. Rev Gastroenterol Disord 2003; 3 Suppl 1: S9-17 [PMID: 12684584]
78. Kim SC, Tonkonogy SL, Albright CA, Tsang J, Balish EJ, Braun J, Huycke MM, Sartor RB. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology 2005; 128: 891-906 [PMID: 15825073]
79. Hedin C, Whelan K, Lindsay JO. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc 2007; 66: 307-315 [PMID: 17637082]
80. Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs 2012; 72: 803-823 [PMID: 22512365 DOI: 10.2165/11632710-0000000 00-00000]
81. de Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv Biochem Eng Biotechnol 2008; 111: 1-66 [PMID: 18461293 DOI: 10.1007/10-2008-097]
82. Mack DR. Probiotics in inflammatory bowel diseases and associated conditions. Nutrients 2011; 3: 245-264 [PMID: 22254095 DOI: 10.3390/nu3020245]
83. Servin AL. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev 2004; 28: 405-440 [PMID: 15374659]
84. Collado MC, Meriluoto J, Salminen S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Lett Appl Microbiol 2007; 45: 454-460 [PMID: 17897389]
85. Dotan I, Rachmilewitz D. Probiotics in inflammatory bowel disease: possible mechanisms of action. Curr Opin Gastroenterol 2005; 21: 426-430 [PMID: 15930982]
86. Sturm A, Rilling K, Baumgart DC, Gargas K, Abou-Ghazalé T, Raupach B, Eckert J, Schumann RR, Enders C, Sonnenborn U, Wiedenmann B, Dignass AU. Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via tolllike receptor 2 signaling. Infect Immun 2005; 73: 1452-1465 [PMID: 15731043]
87. Groeger D, O'Mahony L, Murphy EF, Bourke JF, Dinan TG, Kiely B, Shanahan F, Quigley EM. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes 2013; 4: 325-339 [PMID: 23842110 DOI: 10.4161/gmic.25487]
88. Oliva S, Di Nardo G, Ferrari F, Mallardo S, Rossi P, Patrizi G, Cucchiara S, Stronati L. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther 2012; 35: 327-334 [PMID: 22150569 DOI: 10.1111/j.1365-2036.2011.04939.x]
89. Ishikawa H, Matsumoto S, Ohashi Y, Imaoka A, Setoyama H, Umesaki Y, Tanaka R, Otani T. Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study. Digestion 2011; 84: 128-133 [PMID: 21525768 DOI: 10.1159/000322977]
90. Hegazy SK, El-Bedewy MM. Effect of probiotics on proinflammatory cytokines and NF-kappaB activation in ulcerative colitis. World J Gastroenterol 2010; 16: 4145-4151 [PMID: 20806430 DOI: 10.3748/wjg.v16.i33.4145]
91. D'Incà R, Barollo M, Scarpa M, Grillo AR, Brun P, Vettorato MG, Castagliuolo I, Sturniolo GC. Rectal administration of Lactobacillus casei DG modifies flora composition and Tolllike receptor expression in colonic mucosa of patients with mild ulcerative colitis. Dig Dis Sci 2011; 56: 1178-1187 [PMID: 20737210 DOI: 10.1007/s10620-010-1384-1]
92. Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med 2010; 10: 13 [PMID: 20398311 DOI: 10.1186/1472-6882-10-13]
93. Fujimori S, Gudis K, Mitsui K, Seo T, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C. A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutrition 2009; 25: 520-525 [PMID: 19201576 DOI: 10.1016/j.nut.2008.11.017]
94. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, Sartor RB. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005; 100: 1539-1546 [PMID: 15984978]
95. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009; 104: 437-443 [PMID: 19174792 DOI: 10.1038/ajg.2008.118]
96. Lee JH, Moon G, Kwon HJ, Jung WJ, Seo PJ, Baec TY, Lee JH, Kim HS. [Effect of a probiotic preparation (VSL#3) in patients with mild to moderate ulcerative colitis]. Korean J Gastroenterol 2012; 60: 94-101 [PMID: 22926120]
97. Osman N, Adawi D, Ahrne S, Jeppsson B, Molin G. Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium. Dig Dis Sci 2004; 49: 320-327 [PMID: 15104378]
98. Rochat T, Bermúdez-Humarán L, Gratadoux JJ, Fourage C, Hoebler C, Corthier G, Langella P. Anti-inflammatory effects of Lactobacillus casei BL23 producing or not a manganesedependant catalase on DSS-induced colitis in mice. Microb Cell Fact 2007; 6: 22 [PMID: 17659075]
99. Geier MS, Butler RN, Giffard PM, Howarth GS. Lactobacillus fermentum BR11, a potential new probiotic, alleviates symptoms of colitis induced by dextran sulfate sodium (DSS) in rats. Int J Food Microbiol 2007; 114: 267-274 [PMID: 17150273]